Strategic Diagnostics' Q3 Revenues Rise on Increased Life Science Sales | GenomeWeb

NEW YORK (GenomeWeb News) – Strategic Diagnostics reported after the close of the market on Thursday that its third-quarter revenues increased around 4 percent and its net loss was significantly trimmed.

For the three-month period ended Sept. 30, Strategic Diagnostics brought in total revenues of $7.2 million, up from $6.9 million for the third quarter of 2008. The increase was due to a 29 percent increase in life science sales to $4.3 million from $3.3 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.